Download PDF
Thromb Haemost 2011; 105(05): 931-932
DOI: 10.1160/TH10-11-0757
Letters to the Editor
Schattauer GmbH

An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients

Patrizia Ferroni
1   Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy
,
Francesca Martini
1   Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy
,
Ilaria Portarena
3   Medical Oncology, Department of Internal Medicine, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
,
Italia Grenga
3   Medical Oncology, Department of Internal Medicine, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
,
Silvia Riondino
1   Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy
,
Francesca La Farina
1   Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy
,
Anastasia Laudisi
3   Medical Oncology, Department of Internal Medicine, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
,
Mario Roselli
2   IRCCS San Raffaele Pisana, Rome, Italy
3   Medical Oncology, Department of Internal Medicine, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
,
Fiorella Guadagni
1   Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy
› Author Affiliations Financial support: This work was partially supported by the Italian Ministry of Health Grants RFPS-2006–7–342220 and ACC-WP 3/1b.
Further Information

Publication History

Received: 25 November 2010

Accepted after minor revision: 28 January 2011

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Di Nisio M, Ferrante N, De Tursi M. et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104: 1049-1054.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Ferroni P, Formica V, Roselli M. et al. Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Curr Vasc Pharmacol 2010; 8: 102-113.
    CrossrefPubMedGoogle Scholar
  • 3 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
    CrossrefPubMedGoogle Scholar
  • 4 Khorana AA, Streiff MB, Farge D. et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-4926.
    CrossrefPubMedGoogle Scholar
  • 5 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
    CrossrefPubMedGoogle Scholar
  • 6 Eichinger S, Heinze G, Jandeck LM. et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism. The Vienna Prediction Model. Circulation 2010; 121: 1630-1636.
    CrossrefPubMedGoogle Scholar
  • 7 Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
    CrossrefPubMedGoogle Scholar
  • 8 Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-320.
    CrossrefPubMedGoogle Scholar
  • 9 Douma RA, van Sluis GL, Kamphuisen PW. et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010; 104: 831-836.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Tripodi A, Legnani C, Lemma L. et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2010; 30: 215-219.
    CrossrefPubMedGoogle Scholar
  • 11 Toulon P, Smirnov M, Triscott M. et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 2009; 124: 137-143.
    CrossrefPubMedGoogle Scholar
  • 12 Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115: 5637-5650.
    CrossrefPubMedGoogle Scholar